IMM-101 + nivolumab

IMM-101 + nivolumab is a **combination immunotherapy regimen** under investigation for advanced/metastatic melanoma. IMM-101 is a suspension of heat-killed whole cell *Mycobacterium obuense* (NCTC 13365), administered intradermally as a non-specific immune modulator that activates several immune cell types involved in anti-tumor responses. Nivolumab is a monoclonal antibody checkpoint inhibitor targeting programmed death-1 (PD-1) receptor, used to block the inhibitory PD-1 pathway and restore T cell-mediated antitumor activity. The combination aims to synergize systemic immune activation through IMM-101 with checkpoint inhibition by nivolumab, potentially enhancing antitumor effects following anti-PD-1 failure or as first-line therapy. The regimen is in clinical trials investigating safety, tolerability, and efficacy, particularly for advanced melanoma. IMM-101 is developed by Immodulon Therapeutics, while nivolumab is developed and commercialized by Bristol Myers Squibb[1][2][3].

Other names

Mycobacterium obuense suspension + nivolumab